[go: up one dir, main page]

TR200202184T2 - Glikojen fosforilaz önleyicilerinden oluşan farmasötik kompozisyonlar - Google Patents

Glikojen fosforilaz önleyicilerinden oluşan farmasötik kompozisyonlar

Info

Publication number
TR200202184T2
TR200202184T2 TR2002/02184T TR200202184T TR200202184T2 TR 200202184 T2 TR200202184 T2 TR 200202184T2 TR 2002/02184 T TR2002/02184 T TR 2002/02184T TR 200202184 T TR200202184 T TR 200202184T TR 200202184 T2 TR200202184 T2 TR 200202184T2
Authority
TR
Turkey
Prior art keywords
glycogen phosphorylase
pharmaceutical compositions
compositions consisting
phosphorylase inhibitors
phosphorylase inhibitor
Prior art date
Application number
TR2002/02184T
Other languages
English (en)
Inventor
Jay Hoover Dennis
Mysore Shanker Ravi
Thomas Friesen Dwayne
Alan Lorenz Douglas
Alan Schriver Nightingale James
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200202184T2 publication Critical patent/TR200202184T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Farmasötik kompozisyonlar, bir glikojen fosforilaz önleyicisi ve en az bir konsantrasyon kuvvetlendirici polimer ihtiva eder. Kompozisyon, glikojen fosforilaz önleyicisi ve konsantrasyon kuvvetlendirici polimerden olusan basit fiziksel bir karisim veya glikojen fosforilaz önleyicisi ve polimerden olusan bir dagilim olabilir.
TR2002/02184T 2000-03-16 2001-03-16 Glikojen fosforilaz önleyicilerinden oluşan farmasötik kompozisyonlar TR200202184T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
TR200202184T2 true TR200202184T2 (tr) 2003-01-21

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/02184T TR200202184T2 (tr) 2000-03-16 2001-03-16 Glikojen fosforilaz önleyicilerinden oluşan farmasötik kompozisyonlar

Country Status (32)

Country Link
US (1) US20010053778A1 (tr)
EP (1) EP1263414A1 (tr)
JP (1) JP2003526654A (tr)
KR (1) KR20020081445A (tr)
CN (1) CN1418089A (tr)
AP (1) AP2002002621A0 (tr)
AR (1) AR027656A1 (tr)
AU (1) AU2001242669A1 (tr)
BG (1) BG107037A (tr)
BR (1) BR0109189A (tr)
CA (1) CA2403241A1 (tr)
CO (1) CO5280087A1 (tr)
CZ (1) CZ20022955A3 (tr)
EA (1) EA200200858A1 (tr)
EE (1) EE200200530A (tr)
HU (1) HUP0204583A2 (tr)
IL (1) IL151320A0 (tr)
IS (1) IS6508A (tr)
MA (1) MA26882A1 (tr)
MX (1) MXPA02009097A (tr)
NO (1) NO20024386L (tr)
OA (1) OA12232A (tr)
PA (1) PA8513601A1 (tr)
PE (1) PE20011184A1 (tr)
PL (1) PL360780A1 (tr)
SK (1) SK12622002A3 (tr)
SV (1) SV2002000343A (tr)
TN (1) TNSN01040A1 (tr)
TR (1) TR200202184T2 (tr)
WO (1) WO2001068055A1 (tr)
YU (1) YU67202A (tr)
ZA (1) ZA200207290B (tr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK8562002A3 (en) * 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
PT1404300E (pt) * 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
KR100759635B1 (ko) 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
KR100664822B1 (ko) 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
MXPA04007438A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
JP2007501218A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
ES2353309T3 (es) 2004-03-08 2011-03-01 Prosidion Ltd. Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa.
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
WO2014031419A1 (en) * 2012-08-24 2014-02-27 Dow Global Technologies Llc Novel esterified cellulose ethers of high molecular weight and homogeneity
RS62676B1 (sr) 2012-09-11 2021-12-31 Medivation Prostate Therapeutics Llc Formulacije enzalutamida
CN105307636A (zh) 2013-07-19 2016-02-03 西佳技术公司 非晶形特考韦瑞制备
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP624A (en) * 1995-06-06 1997-12-19 Pfizer Substituted n-(indole-2-carbonyl)-b- alanimamides and derivatives as antidiabetic agents.
EP0832065B1 (en) * 1995-06-06 2001-10-10 Pfizer Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
EA200200858A1 (ru) 2003-02-27
JP2003526654A (ja) 2003-09-09
SK12622002A3 (sk) 2004-02-03
BR0109189A (pt) 2003-05-27
US20010053778A1 (en) 2001-12-20
CN1418089A (zh) 2003-05-14
SV2002000343A (es) 2002-07-03
AR027656A1 (es) 2003-04-09
YU67202A (sh) 2006-01-16
CA2403241A1 (en) 2001-09-20
HUP0204583A2 (hu) 2003-04-28
CZ20022955A3 (cs) 2003-09-17
TNSN01040A1 (fr) 2005-11-10
PE20011184A1 (es) 2001-11-15
EP1263414A1 (en) 2002-12-11
BG107037A (bg) 2003-04-30
IL151320A0 (en) 2003-04-10
MA26882A1 (fr) 2004-12-20
NO20024386D0 (no) 2002-09-13
AP2002002621A0 (en) 2002-09-30
NO20024386L (no) 2002-11-13
PA8513601A1 (es) 2004-08-31
EE200200530A (et) 2004-04-15
WO2001068055A1 (en) 2001-09-20
OA12232A (en) 2006-05-10
PL360780A1 (en) 2004-09-20
MXPA02009097A (es) 2003-03-12
CO5280087A1 (es) 2003-05-30
AU2001242669A1 (en) 2001-09-24
IS6508A (is) 2002-08-16
ZA200207290B (en) 2003-09-11
KR20020081445A (ko) 2002-10-26

Similar Documents

Publication Publication Date Title
TR200202184T2 (tr) Glikojen fosforilaz önleyicilerinden oluşan farmasötik kompozisyonlar
TW200738817A (en) Blends of biopolymers with acrylic copolymers
TR200200606T2 (tr) Lipaz inhibitörleri içeren dispersiyon terkipleri.
TR201908551T4 (tr) Yakıt bileşimleri.
ATE507822T1 (de) Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
CR11167A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos
BR0207296A (pt) Composição para revestimento
ATE310717T1 (de) In basen lösliches verpackungsmaterial zur verwendung bei giessbaren, zementartigen zusammensetzungen
AR023641A1 (es) Una composicion de copolimeros de propileno cristalinos, un procedimiento para prepararla, y una pelicula o lamina monocapa o multicapa que comprende adicha composicion
ATE315069T1 (de) Wässrige vinyl-polymer-zusammensetzungen
MY144626A (en) Semiconductor-nanocrystal/conjugated polymer thin films
NO20011017L (no) Polymeriserings-inhibitering av styren-monomerer
WO2006014647A3 (en) Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
ATE337367T1 (de) Fluorelastomerer kaltschrumpfgegenstand
EA200702355A1 (ru) Композиции гомо- или сополимеров альфа-олефинов
BR0207646A (pt) Composição estabilizadora para polìmeros halogenados, uso da mesma e polìmeros que compreendem tais composições
EE200100287A (et) Puidukaitsevahendite lahused
TR200002269T2 (tr) Katı yakıt katkıları.
ITRM20040166A1 (it) Ceppi batterici lab con proprieta' probiotiche e composizioni che contengono gli stessi.
TR200001724T2 (tr) 5-HT1F Agonistleri
TR200002871T2 (tr) Polimer Kompozisyonları
TR200705146T1 (tr) Monoamin Yükselmesinin Engellenmesi
DK1869100T3 (da) Vandige vinylcoatingsammensætninger
EA200300128A1 (ru) Фармацевтические композиции, содержащие карбонат лития
AU2002364348A8 (en) Composition comprising at least an alkanolamide for inhibiting langerhans cell migration, and uses thereof